Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

Slides:



Advertisements
Similar presentations
Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21.
Advertisements

CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.
Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms
Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.
Genomic alterations in breast cancer cell line MDA-MB-231.
Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR  Marie.
Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,
A. glioblastoma with high (+++) KIT protein expression.
Genetic and pharmacologic inactivation of KSR1 radiosensitizes A431 cells in vitro to the lethal effect of ionizing radiation. Genetic and pharmacologic.
Aglaya G. Iyevleva, MD, PhD  Journal of Thoracic Oncology 
Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol. Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol.
Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.
(A) yellow cDNA comparison among wild-type and ch mutants
A–c) Case 1, with epidermal growth factor receptor (EGFR) exon 21 mutations (V843I and L858R). a) Pedigree chart. a–c) Case 1, with epidermal growth factor.
A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =
BRCA1 and BRCA2 Testing: Weighing the Demand against the Benefits
Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.
GA blocks HIF activity and reduces HIF target expression.
A, IGFBP-3 knockdown via siRNA using real-time qRT-PCR analysis.
Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.
A, rate of proliferation of PC3 prostate cancer cells is greatly reduced by treatment with oligomers containing CpG motifs, as assessed by (a) soft agar.
BRCA1 promoter methylation detected in the peripheral blood and corresponding tumor. BRCA1 promoter methylation detected in the peripheral blood and corresponding.
Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.
Expression analysis of IGFBP-3 using human whole-genome microarray.
Antitumor immunity caused by DS-8201a.
VP16-E2 is a more potent transcriptional activator than Gal4-VP16.
A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.
GS87 demonstrates efficacy in a circulating AML mouse model system.
Interaction of MAPJD with E-box sequence of the RIOK1 gene.
Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.
Analysis of thermal stability and aggregation properties before and after disulfide stabilization of the pMHCI complex. Analysis of thermal stability and.
CAT displays very high in vivo stability as exemplified by a rat PK study. CAT displays very high in vivo stability as exemplified by a rat.
Illustration of working hypothesis and biological impact of retained introns. Illustration of working hypothesis and biological impact of retained introns.
EGFR and cetuximab sensitivity of SCCUAT
KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,
Correlation of miR-21 expression levels with DEGs in 28 bladder cancer cell lines. Correlation of miR-21 expression levels with DEGs in 28 bladder cancer.
Induction of cell death in prostate cancer cells by SAHA and ZOL
TDP1 and TOP1 protein levels correlate positively with TDP1 and TOP1 mRNA levels in colorectal cancer cell lines. TDP1 and TOP1 protein levels correlate.
Histone modification status at the Tβ4 promoter and at the protein level in the HuH7 sublines. Histone modification status at the Tβ4 promoter and at the.
Structural model of Y764_V765insHH.
Immunohistochemical detection of nuclear and cytoplasmic YB-1 in osteosarcoma and synovial sarcoma. Immunohistochemical detection of nuclear and cytoplasmic.
Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,
GA reduces the growth of Caki-1 tumor xenografts.
Modeling of EGFR exon 20 insertions using the 3-dimensional structure of the EGFR kinase domain predicts different interactions with the erlotinib-binding.
Colony formation of K-562 cells after 24 h (upper panel) or 48 h (lower panel) exposure to ErPC3 (20 μm) and ASO-bcr (10 μm), respectively. Colony formation.
Immunohistochemical analysis of dUTPase in human breast adenocarcinoma
Discovered and replicated positive correlation between miR-193b
Effect of miRNA mimic on platinum sensitivity.
Inhibition of EGFR kinase activity and autophosphorylation by Iressa.
Tumor and serum levels of murine IL-12.
Xenograft regrowth studies.
GR CAFs modulate the EGFR-TKI response in cocultured tumor cells.
Location of common clinically relevant mutations in EGFR
Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.
Replication stress inhibition synergizes with DNA damaging agents in human cells. Replication stress inhibition synergizes with DNA damaging agents in.
Effect of coapplication of dexrazoxane and doxorubicin on DSB formation, TOP2A protein level, and apoptosis. Effect of coapplication of dexrazoxane and.
A, P causes G2-M arrest with apoptosis in asynchronous population of PC-3 when exposed to 1.5 and 5 μmol/L P for various time points. A, P
A and B, comparison of time course of TFF1 mRNA induction under estrogen-withdrawn (denoted ph−/ES−) and estrogenic medium (denoted ph+/ES+) conditions.
Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.
A, tumor growth studies in H1975 tumor–bearing mice.
Number of identical D-loop DNA clones detected in 10 DNA clones derived from liver tumor tissues. Number of identical D-loop DNA clones detected in 10.
WP1066 inhibits the progression of OCIM2 cells through the cell cycle.
Structures of wild-type and mutated recombinant CDX2.
Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.
Prevalence of germline T790M.
A and B, two blocks from the original specimen used for TMA demonstrated areas with varying patterns of ALK rearrangement and KRAS mutation status. A and.
AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. A,
A–D, FGFR3 gatekeeper mutations detected in 4 patients.
Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.
Fig. 3 Genome editing of the MSTN gene.
Presentation transcript:

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations detected within the same time frame. Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations detected within the same time frame. Insertions in exon 20 of EGFR show higher heterogeneity compared to both HER2 and EGFR exon 19. Most insertions in HER2 are represented by the A775_G776insYVMA, whereas insertions in exon 19 of EGFR all share the inserted sequence PVAI and are located in the same region I744-E746. Maria E. Arcila et al. Mol Cancer Ther 2013;12:220-229 ©2013 by American Association for Cancer Research